Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
IPO Year: 2018
Exchange: NASDAQ
Website: twistbioscience.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/4/2024 | $53.00 | Buy | Guggenheim |
| 1/17/2024 | $25.00 → $45.00 | Neutral → Buy | Goldman |
| 9/27/2023 | $27.00 | Buy | Berenberg |
| 1/5/2023 | $33.00 | Sector Outperform | Scotiabank |
| 1/3/2023 | $28.00 → $36.00 | In-line → Outperform | Evercore ISI |
| 3/2/2022 | Outperform | Cowen | |
| 2/7/2022 | $130.00 → $75.00 | Overweight | Barclays |
| 2/7/2022 | $110.00 → $70.00 | Market Perform | SVB Leerink |
| 10/15/2021 | Outperform | Cowen | |
| 6/29/2021 | Outperform | William Blair |
S-8 - Twist Bioscience Corp (0001581280) (Filer)
10-K - Twist Bioscience Corp (0001581280) (Filer)
8-K - Twist Bioscience Corp (0001581280) (Filer)
8-K - Twist Bioscience Corp (0001581280) (Filer)
10-Q - Twist Bioscience Corp (0001581280) (Filer)
8-K - Twist Bioscience Corp (0001581280) (Filer)
10-Q - Twist Bioscience Corp (0001581280) (Filer)
8-K - Twist Bioscience Corp (0001581280) (Filer)
144 - Twist Bioscience Corp (0001581280) (Subject)
144 - Twist Bioscience Corp (0001581280) (Subject)
Pure Biologics' exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumorsTwist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that the first patient has been dosed in Pure Biologics' exploratory Phase 0 clinical study of PBA-0405. PBA-0405 is a fully human IgG1 antibody that was discovered using Twist Biopharma Solutions' synthetic antibody phage display libraries. Twist Biopharma Solutions, a division of Twist Bioscience, provides an integrated offering of in vitro, in vivo, and in silico tools for antibody discovery research. This ex
In a recent letter to investors, Cathie Wood, the CEO of ARK Invest, highlighted the potential of the company’s flagship fund, ARK Innovation ETF (NYSE:ARKK), despite its recent underperformance. What Happened: Wood, in her letter, acknowledged that ARKK’s performance has been impacted by the shift in focus from the “Magnificent Six” to multiomics stocks, which have been adversely affected by the prospect of prolonged high interest rates. Despite this, ARKK’s valuation has dropped to a level that Wood believes is indicative of “deep value territory” over a five-year investment horizon. Wood pointed out that ARKK’s valuation, as of June, was 25.5x, the lowest it has been since Febru
Goldman Sachs analyst Matthew Sykes maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $45 to $55.
On Tuesday, Cathie Wood-led Ark Invest made significant adjustments to its portfolio, offloading a substantial number of shares in Tesla Inc (NASDAQ:TSLA) and scooping up a hefty stake in Palantir Technologies Inc (NYSE:PLTR). The Tesla Trade Ark Invest reduced its stake in Tesla across two of its ETFs — ARK Innovation ETF (NYSE:ARKK) and ARK Next Generation Internet ETF (NYSE:ARKW). The firm sold 56,425 and 6,442 shares respectively, the transaction was valued at $14.54 million. On Tuesday, Tesla shares closed 10.2% higher at $231.26, driven higher by the second-quarter delivery report of the company. The numbers came ahead of the consensus estimate. This move comes despite Wood’s
Analysts' ratings for Twist Bioscience (NASDAQ:TWST) over the last quarter vary from bullish to bearish, as provided by 8 analysts. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 6 0 0 0 Last 30D 0 1 0 0 0 1M Ago 2 0 0 0 0 2M Ago 0 4 0 0 0 3M Ago 0 1 0 0 0 Analysts have recently evaluated Twist Bioscience and provided 12-month price targets. The average target is $50.12, accompanied by a high estimate of $65.00 and a low estimate of $40.00. Surpassing the previous averag
Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and raises the price target from $45 to $60.
TD Cowen analyst Steven Mah maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $55 to $65.
These mid-cap stocks were the best performers in the last week. Are they in your portfolio? Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares soared 29.13% in the last week after reporting that its transfusion-dependent (TD) alpha-or beta-thalassemia study met primary endpoint. Several analysts raised their forecasts after the announcement. Verint Systems Inc. (NASDAQ:VRNT) shares are zoomed 22.40% after the company on Tuesday reported better-than-expected Q1 financial results and issued strong FY25 guidance. Novavax Inc (NASDAQ:NVAX) shares gained 21.54% in the last week after the U.S. Food and Drug Administration’s advisory committee voted to recommend updated vaccines for JN.1-line
TB206-001 shown to be a high-affinity, cross-reactive humanized antibody antagonist of A2AR with in vivo tumor suppressing activityTB206-001 available for out-licensingTwist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the publication of a study detailing the discovery of TB206-001, a first-in-class antibody targeting adenosine A2A receptor (A2AR), a promising molecular target that could enhance cancer immunotherapy. The study titled, "Discovery of a potent, selective, and tumor-suppressing antibody antagonist of adenosine A2A receptor", was published in the journal
4/A - Twist Bioscience Corp (0001581280) (Issuer)
4/A - Twist Bioscience Corp (0001581280) (Issuer)
4/A - Twist Bioscience Corp (0001581280) (Issuer)
4/A - Twist Bioscience Corp (0001581280) (Issuer)
4/A - Twist Bioscience Corp (0001581280) (Issuer)
4/A - Twist Bioscience Corp (0001581280) (Issuer)
4 - Twist Bioscience Corp (0001581280) (Issuer)
4 - Twist Bioscience Corp (0001581280) (Issuer)
4 - Twist Bioscience Corp (0001581280) (Issuer)
4 - Twist Bioscience Corp (0001581280) (Issuer)
For Immediate Release: March 26, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On March 23, 2021, the FDA issued an emergency use authorization (EUA) to the Twist Bioscience Corporation for their SARS-CoV-2 NGS Assay. The SARS-CoV-2 NGS Assay is a next-generation sequencing (NGS) based test for the identification of SARS-CoV-2 RNA from respirato
SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)
SC 13G - Twist Bioscience Corp (0001581280) (Subject)
SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)
SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)
SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)
SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)
SC 13G - Twist Bioscience Corp (0001581280) (Subject)
SC 13G - Twist Bioscience Corp (0001581280) (Subject)
SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)
SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)
Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the fourth quarter and full year fiscal 2024 ended September 30, 2024. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal fourth quarter and full year 2024 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. E
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3, 2024 at 10:00 a.m. Eastern Time in Coral Gables, Florida. The fireside chat will be webcast live and can be accessed by visiting the "Investor Calendar" page of the investor relations section of the company's website here. A replay of the presentation will be archived for a period of 30 days fo
As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ:TWST) ("Twist" or the "Company"), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 147,800 equity awards, consisting of 110,300 restricted stock units ("RSUs") to 43 recently hired individuals and an individually negotiated award of up to 37,500 performance stock units ("PSUs") to Colby Souders, a recently hired VP, in each case as an inducement material to their acceptance of employment with Twist. The employment inducement awards were granted under Twist's Inducement Equity Incentive P
VANCOUVER, Wash. and SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI) a data-first generative AI drug creation company, and Twist Bioscience Corporation (NASDAQ:TWST) a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today unveiled a collaboration to design a novel therapeutic using generative AI. "Bringing together two leaders in biotechnology innovation represents an opportunity to accelerate pharmaceutical R&D," said Absci Founder & CEO Sean McClain. "We are excited to strengthen our relationship with Twist and leverage the power of our shared platforms to bring better bio
Normalization by Ligation™ library preparation technology processes thousands of samples at low cost with enhanced multiplexing and novel streamlined workflow Designed with a Twist-developed enzyme specifically to increase adoption of NGS workflows in high throughput applications Collaboration with Gencove to offer access to software to perform genomic analysis, enabling an end-to-end sample to variant call workflow Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of the FlexPrep™ Ultra-High Throughput Library Preparation Kit, designed with a propri
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 fourth quarter and full year ended September 30, 2024, before the opening of the market on November 18, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to
Twist to retain all upfront, service and other revenue earned under antibody discovery and biopharma solutions agreements as well as half of future milestones and royalties Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has entered into a royalty purchase agreement with XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator. Under the terms of the agreement, XOMA Royalty will provide Twist Bioscience an upfront payment of $15 million in cash in exchange for the right to receive half of the future potential milestone and royalty payments res
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mike Fero, Ph.D., as chief information officer. Dr. Fero brings more than 30 years of experience leading startups, developing commercial software, researching biology and physics and working in fast-paced deep-tech businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241008118663/en/Mike Fero, Ph.D., CIO of Twist Bioscience (Photo: Business Wire) "Mike's extensive background in building and configuring scalable enterprise softwar
Wilsonville, OR facility LEED v4.1 Operations + Maintenance certified Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that the U.S. Green Building Council (USGBC) awarded the company's Wilsonville, OR facility LEED certification, meeting sustainability standards for its building, operations and maintenance. "We founded Twist to improve health and sustainability, and every day we work toward that mission by providing our customers with products to enable them to build a better world," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "Last
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today released its 2024 corporate responsibility report detailing Twist's approach to sustainability, social responsibility and ethics. The report highlights Twist's ongoing commitment to advancing sustainable initiatives to best serve customers, communities and the planet. "At Twist, we're always looking to the future and improving what we do, whether that's delivering new products, providing development opportunities for our employees, continuing to hold ourselves to the highest standards of biosecurity or our efforts in sustai
Guggenheim initiated coverage of Twist Bioscience with a rating of Buy and set a new price target of $53.00
Goldman upgraded Twist Bioscience from Neutral to Buy and set a new price target of $45.00 from $25.00 previously
Berenberg initiated coverage of Twist Bioscience with a rating of Buy and set a new price target of $27.00
Scotiabank initiated coverage of Twist Bioscience with a rating of Sector Outperform and set a new price target of $33.00
Evercore ISI upgraded Twist Bioscience from In-line to Outperform and set a new price target of $36.00 from $28.00 previously
Cowen resumed coverage of Twist Bioscience with a rating of Outperform
Barclays reiterated coverage of Twist Bioscience with a rating of Overweight and set a new price target of $75.00 from $130.00 previously
SVB Leerink reiterated coverage of Twist Bioscience with a rating of Market Perform and set a new price target of $70.00 from $110.00 previously
Cowen resumed coverage of Twist Bioscience with a rating of Outperform
William Blair initiated coverage of Twist Bioscience with a rating of Outperform
Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the fourth quarter and full year fiscal 2024 ended September 30, 2024. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal fourth quarter and full year 2024 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. E
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 fourth quarter and full year ended September 30, 2024, before the opening of the market on November 18, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to
– Record revenue of $81.5M in 3QFY24, an increase of 28% over $63.7M in 3QFY23 – – Gross margin improved to 43.3% in 3QFY24, increasing approximately 900 basis points over 34.4% in 3QFY23 – — Increased FY 2024 revenue guidance to approximately $310M to $311M; FY 2024 gross margin guidance at high end of the range at approximately 42.0% — — Company to host conference call today at 8:00 a.m. Eastern Time — Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the third quarter of fiscal 2024 ended June 30, 2024. "We
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 third quarter ended June 30, 2024, before the opening of the market on Friday, August 2, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference
– Record revenue of $75.3M in 2QFY24, an increase of 25% over $60.2M in 2QFY23 – – Orders increased to $93.2M in 2QFY24, growth of 45% over $64.2M in 2QFY23 – — Increased FY 2024 revenue guidance to a range of $300M to $304M; Increased FY 2024 gross margin guidance to a range of 41.5 to 42.0% — — Company to host conference call today at 4:30 p.m. Eastern Time — Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2024 ended March 31, 2024. "This was another very strong quarter for Twi
Company to host conference call at 4:30 p.m. ET Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 second quarter ended March 31, 2024, after market close on Thursday, May 2, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call throu
– Record revenue of $71.5M in 1QFY24, an increase of 32% over $54.2M in 1QFY23 – – Orders increased to $77.5M in 1QFY24, an increase of 19% over 1QFY23 – — Increased FY 2024 revenue guidance to $288M to $293M; Increased FY 2024 gross margin guidance to 40% to 41% – Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the first quarter of fiscal 2024 ended December 31, 2023. "We're starting fiscal 2024 off strong with record revenue of $71.5 million for the first fiscal quarter, coming in above our projection, with
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 first quarter ended December 31, 2023, before the opening of the market on Friday, February 2, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call through the Investor Relations secti
-- Record revenue of $245.1 million in Fiscal 2023; Increase of 20% over $203.6 million in Fiscal 2022 -- -- Orders increased to $264 million in Fiscal 2023; Increase of 17% over $226.4 million in Fiscal 2022 -- — Expect revenue in the range of $285 million to $290 million for full year Fiscal 2024 -- Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the fourth quarter and full year fiscal 2023 ended September 30, 2023. "Fiscal 2023 was a defining year for Twist as we grew our revenue 20% year over year with str
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2023 fourth quarter and full year ended September 30, 2023, before the opening of the market on Friday, November 17, 2023. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call through the Investo
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mike Fero, Ph.D., as chief information officer. Dr. Fero brings more than 30 years of experience leading startups, developing commercial software, researching biology and physics and working in fast-paced deep-tech businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241008118663/en/Mike Fero, Ph.D., CIO of Twist Bioscience (Photo: Business Wire) "Mike's extensive background in building and configuring scalable enterprise softwar
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Adam Laponis as chief financial officer. Mr. Laponis brings experience across small cap and Fortune 50 companies along with a track record of collaborating across teams to drive profitable growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240105333128/en/Adam Laponis, chief financial officer of Twist Bioscience (Photo: Business Wire) "Adam's deep financial acumen and strategic planning expertise across diverse businesses make him
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mark Buck as senior vice president, operations. Mr. Buck brings experience improving manufacturing efficiency and driving revenue and margin through managing supply chain and operations, including planning, quality, procurement and logistics. "Building on the foundation of his time serving in the United State Marine Corps and drawing from military efficiency, Mark has established a career in industry developing and optimizing operational processes and requirements that enable scale for multiple
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Chet Gandhi as chief information officer. Mr. Gandhi brings a wealth of experience in leading and executing software and information technology strategies to enable the growth of global public and private companies. "With a strong track record of success, Chet's expertise will play a crucial role in driving automation and supporting Twist's expansion efforts as we strive to grow our customer base from over three thousand to over one hundred thousand," said Emily M. Leproust, Ph.D., CEO and co-f
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Robert Werner as chief accounting officer. "Rob has a proven track record of leading corporate and technical accounting, including for global companies as they grow in revenue," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "He will be an invaluable addition as Twist continues to gain market share and execute against our plan to achieve adjusted EBITDA breakeven for the core and biopharma businesses at the close of the fiscal fourth quarter of 2024." "I have spent the
BigHat Biosciences, a biotechnology company designing safer, more effective next-generation antibody therapies for patients using machine learning and synthetic biology, today announced that Rob Chess has been elected to BigHat's board of directors. Rob brings valuable experience in corporate biotech leadership and business strategy, from having led innovative and diverse teams from inception to successful exits to serving on the boards of multiple private and public life sciences companies. "We look forward to leveraging Rob's deep expertise in drug discovery and development to accelerate our work creating better antibody therapies for patients," said Mark DePristo, PhD., BigHat's CEO and
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Steffen Hellmold to the newly created position of senior vice president, business development, data storage. "We have made significant technological advances in our DNA data storage division and are now focused on laying the foundation for commercialization of this disruptive and important storage solution. The addition of Steffen to the team will help to define our commercialization strategy and build important relationships as we move towards more accessible DNA data storage solutions," commen
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Dennis Cho as senior vice president, general counsel and chief ethics and compliance officer. Mr. Cho brings more than 25 years of corporate legal experience, most of which has been in the biotech industry. "Dennis is a giant of biopharma deals with a proven track record in, and commitment to, the biotech industry. He has provided counsel on all types of transactions and collaborations, which makes him ideal for the role at Twist," commented Emily M. Leproust, Ph.D., CEO and co-founder of Twist
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it appointed Melissa Starovasnik, Ph.D. to its board of directors. Dr. Starovasnik most recently served as Senior Scientific Advisor, Research at Genentech, Inc. and brings nearly three decades of experience in protein and antibody drug discovery and development. "Melissa's extensive leadership and scientific experience will be valuable to Twist as we leverage our DNA platform to support our broad base of customers across the synthetic biology and biopharmaceutical industries," said Emily M. Leproust, Ph.D., CEO a